Dr. Takebe joined CTEP in September 2007 as a Senior Investigator at the Investigational Drug Branch, where she works with academic investigators and industry collaborators to carry out the clinical development of promising new cancer therapies. Her current portfolio includes agents causing programmed cell death, cancer stem cell targeting agents, and src inhibitors. Dr. Takebe received her M.D. and Ph.D. degrees from Hirosaki University, Japan in 1988 and 2002, respectively. She completed her medical Hematology/Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in 1997, and a Postdoctoral Research Fellowship at the Memorial Sloan-Kettering Institute in 1999. Her research at that time focused on drug resistance gene retroviral gene transfer into hematopoietic stem cells for myeloprotection. In 1999, she joined the Blood and Stem Cell Transplant Program in the Department of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland. There she conducted clinical trials in the area of multiple myeloma and leukemia involving autologous and allogeneic transplants. Her laboratory research centered on experimental therapeutics, developing novel animal models for leukemia, and hematopoietic stem cell ex vivo expansion using umbilical cord blood stem cells. Dr. Takebe has served as a reviewer for journals such as Stem Cells, American Journal of Hematology, and Leukemia Research. She also served as a reviewer for the Committee of Stem Cell Research Grants. She is board certified in both hematology and oncology.
National Cancer Institute
Executive Plaza North, Suite 7124
Rockville MD, 20852-7426